Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: A phase II study

British Journal of Cancer

Volumn 93, Issue 4, 2005, Pages 406-411

  Conte, P F ^a   Donati, S ^b   Gennari, A ^b   Guarneri, V ^a   Orlandini, C ^b   Rondini, M ^b   Roncella, M ^b   Marini, L ^c   Collecchi, P ^b   Viacava, P ^b   Naccarato, A G ^b   Degli Esposti, R ^d   Bonardi, S ^e   Bottini, A ^e   Saracchini, S ^f   Tumolo, S ^f   Gullo, G ^g   Santoro, A ^g   Crino, L ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Ely Lilly Italy   (Italy)

^d BELLARIA HOSPITAL   (Italy)

^e CREMONA HOSPITAL   (Italy)

^f S Maria Degli Angeli Regional Hospital   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Breast cancer; Epirubicin; Gemcitabine; Pathological complete response; Primary chemotherapy; Taxol

Indexed keywords

EPIRUBICIN; GEMCITABINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GET PROTOCOL; TAXOID; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; BREAST TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 24944535396     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602723     Document Type: Article

References (49)

1. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W, Nasiri N, Dowsett M (2003) Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89: 1035-1041
2. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF (1995) Expression of ras, p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266
3. Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF (2003) Accelerated vs standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14: 227-232
4. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N, National Surgical Adjuvant Breast and Bowel Project Protocol B-27 (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174
5. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100
6. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G, Valagussa P (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545
7. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN (2003) Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 98: 1150-1160
8. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L (2002) Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8: 461-468
9. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92: 147-155
10. Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crino L, Conte PF (2004) Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer 90: 31-35
11. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063
12. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369
13. Collecchi P, Baldini E, Giannessi P, Naccarato AG, Passoni A, Gardin G, Roncella M, Evangelista G, Bevilacqua G, Conte PF (1998) Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumor regression and biological markers. Eur J Cancer 34: 1701-1704
14. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, Sacchini V, Veronesi P, Zurrida S, Orecchia R, Goldhirsch A (1999) Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35: 574-579
15. Conte PF, Gennari A, Donati S, Salvadori B, Baldini E, Bengala C, Pazzagli I, Orlandini C, Danesi R, Fogli S, Del Tacca M (2001) Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 68: 171-179
16. Conte PF, Gennari A, Santoro A, Bottini A, Crino L, Tumolo S, Donati S, Rondini M, Orlandini C, Marini L, for the GET Preoperative Group (2003) Induction chemotherapy in operable breast cancer: a multicenter Italian phase II study with the GET regimen. Proc Am Soc Clin Oncol 22: 35 (abstract 140)
17. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Penault-Llorca F, Buyse M, Pouillart P (2004) Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22: 4958-4965
18. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith K, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 23: 2477-2492
19. Ellis MJ, Coop A, Singh B, Mauriac L, Llombart-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808-3816
20. Esteva FJ, Hortobagyi GN (2004) Prognostic molecular markers in early breast cancer. Breast Cancer Res 6: 109-118
21. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493
22. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
23. Fogli S, Danesi R, Gennari A, Donati S, Conte PF, Del Tacca M (2002) Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol 13: 919-927
24. Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B, Dieras V (2003) Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14: 1623-1628
25. Gianni L, Baselga J, Eiermann W, Guillen Porta V, Semiglazov V, Garcia-Conde J, Zambetti M, Valagussa P, Bonadonna G (2002) First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): effects of primary systemic therapy (PST) on local - regional disease. Proc Am Soc Clin Oncol 21: 34 (abstract 132)
26. Gradishar WJ (1997) Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11: 15-18
27. Hamm J, Wilson J, Lembersky BC, Robidoux A, Raymond J, Kardinal C, DiNunno L, Melemed A, Geyer Jr CE, Paik S, Wolmark N (2003) Neoadjuvant chemotherapy with gemcitabine(G), epirubicin(E), and paclitaxel(T) in locally advanced breast cancer(LABC): a phase II trial of the NSABP Foundation Research Group. Breast Cancer Res Treat 82: S53 (abstract 235)
28. Hortobagyi G, Buzdar AU (1997) Locally advanced breast cancer. In Textbook of Breast Cancer. A Clinical Guide to Therapy, Bonadonna G, Hortobagyi GN, Gianni AM (eds) pp 155-168. Martin Dunitz: London
29. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International Expert Panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600-2608
30. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathological tumor and axillary ymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
31. Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10: 6764-6769
32. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC (1997) Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600
33. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Hugh J, Nabholtz JM, Loret C, Rupin M, Blitz S, Riva A, Vogel C, on behalf of the BCIRG 001 Investigators (2003) TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 82(Suppl 1) (abstract 43)
34. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant vs adjuvant systemic treatment in breast cancer: an a-analysis. J Natl Cancer Inst 97: 188-194
35. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomised trial with a 124-month follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47-52
36. Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegele P (2001) Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 7: 1577-1581
37. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, Palangie T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P (2000) Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83: 1480-1487
38. Pusztai L, Ayers M, Symmans FW, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi GN, Stec J (2003) Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22: 1 (abstract 1)
39. Schneeweiss A, Huober J, Sinn HP, von Fournier D, Rudlowski C, Beldermann F, Krauss K, Solomayer E, Hamerla R, Wallwiener D, Bastert G (2004) Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur J Cancer 40: 2432-2438
40. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P, Garcio-Giralta E, Salmon RJ, de la Rochefordière A, Campana F, Pouillart P (1994) Neoadjuvant vs adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30: 645-652
41. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466
42. Smith IE, A'Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, O'Brien ME, Mansi JL, Wilson CB, Robinson AC, Murray PA, Price CG, Perren TJ, Laing RW, Bliss JM, TOPIC Trial Group (2004) A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15: 751-758
43. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S (1995) High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429
44. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Center. Cancer Chemother Pharmacol 40: 321-329
45. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
46. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19: 4224-4237
47. van't Veer LJ, Dai H, Van De Vijer MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
48. von Minckwitz G, Raab G, Blohmer JU, Gerber B, Lohr A, Costa SD, Eidtmann H, Hilfrich J, Jackisch C, Kaufmann M, the German Breast Group (GBG) (2003) In vivo chemosensitivity-adapted neoadjuvant chemotherapy (docetaxel-doxorubicin- cyclophosphamide followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: results of the GEPAR-TRIO randomized pilot study. Breast Cancer Res Treat 82: S54 (abstract 236)
49. Zielinski C, Beslija S, Mrsic-Krmpotic Z, Jassem J, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Brodowicz T (2003) Gemcitabine/epirubicin/ paclitaxel (GET) vs 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer (MBC): demographics of a randomized, multicenter phase III trial of the Central European Cooperative Oncology Group (CECOG). Proc Am Soc Clin Oncol 22: 7, 26a